Jun 2014

ablynx

Joint Bookrunner

41.7 million

Accelerated Bookbuild Offering

Ablynx

Ablynx is a listed Belgian biotech focused on the discovery and development of innovative products for serious diseases, including inflammation, haematology and oncology

Ablynx placed 4,908,332 new shares to fund ongoing and future clinical trials
Kempen & Co acted as Joint Bookrunner and generated significant demand resulting in the upsizing of the deal from an initial €30m at launch to a total of €41.7m